WO2001091792A3 - Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network - Google Patents

Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network Download PDF

Info

Publication number
WO2001091792A3
WO2001091792A3 PCT/IB2000/002077 IB0002077W WO0191792A3 WO 2001091792 A3 WO2001091792 A3 WO 2001091792A3 IB 0002077 W IB0002077 W IB 0002077W WO 0191792 A3 WO0191792 A3 WO 0191792A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
animal
inducing
adhesion molecule
binding agent
Prior art date
Application number
PCT/IB2000/002077
Other languages
French (fr)
Other versions
WO2001091792A2 (en
WO2001091792A9 (en
Inventor
Ragupathy Madiyalakan
Antoine A Noujaim
Beatrice Leveugle
Original Assignee
Altarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Inc filed Critical Altarex Inc
Priority to AU90162/01A priority Critical patent/AU782952C/en
Priority to CA002383432A priority patent/CA2383432A1/en
Priority to EP00993870A priority patent/EP1333859A2/en
Priority to JP2001587805A priority patent/JP2004507459A/en
Priority to IL14835100A priority patent/IL148351A0/en
Publication of WO2001091792A2 publication Critical patent/WO2001091792A2/en
Publication of WO2001091792A9 publication Critical patent/WO2001091792A9/en
Publication of WO2001091792A3 publication Critical patent/WO2001091792A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed are compositions for reducing an immune condition, such as inflammation or cancer, in an animal suffering from the immune condition or predisposed to suffer from the immune condition. The compositions comprise a binding agent that specifically binds to an adhesion molecules expressed on the surface of or released by a blood-borne cell or an endothelial cell lining a blood vessel, wherein the binding agent induces an immune response in the animal to the binding agent. Additional disclosed compositions comprise an agent that is capable of reducing inflammation and reducing cancer in an animal when administered to the animal in a therapeutically effective amount. Also disclosed are methods for administering such compositions to an animal suffering from or predisposed to suffer from the immune condition.
PCT/IB2000/002077 1999-08-25 2000-08-25 Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network WO2001091792A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU90162/01A AU782952C (en) 1999-08-25 2000-08-25 Therapeutic immune condition compositions and methods
CA002383432A CA2383432A1 (en) 1999-08-25 2000-08-25 Therapeutic immune condition compositions and methods
EP00993870A EP1333859A2 (en) 1999-08-25 2000-08-25 Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network
JP2001587805A JP2004507459A (en) 1999-08-25 2000-08-25 Compositions and methods for treating immunological conditions
IL14835100A IL148351A0 (en) 1999-08-25 2000-08-25 Therapeutic immune condition compositions and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15065299P 1999-08-25 1999-08-25
US60/150,652 1999-08-25

Publications (3)

Publication Number Publication Date
WO2001091792A2 WO2001091792A2 (en) 2001-12-06
WO2001091792A9 WO2001091792A9 (en) 2003-01-30
WO2001091792A3 true WO2001091792A3 (en) 2003-05-30

Family

ID=22535450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/002077 WO2001091792A2 (en) 1999-08-25 2000-08-25 Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network

Country Status (6)

Country Link
EP (1) EP1333859A2 (en)
JP (1) JP2004507459A (en)
AU (1) AU782952C (en)
CA (1) CA2383432A1 (en)
IL (1) IL148351A0 (en)
WO (1) WO2001091792A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103212071B (en) * 2005-08-25 2017-12-12 亚利桑那大学董事会 Stem cell fusion model of carcinogenesis
MX2022009130A (en) 2020-01-24 2022-08-22 Pfizer Anti-e-selectin antibodies, compositions and methods of use.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025647A1 (en) * 1992-06-15 1993-12-23 The Procter & Gamble Company Liquid laundry detergent compositions with silicone antifoam agent
WO1998056416A1 (en) * 1997-06-09 1998-12-17 Yeda Research And Development Co. Ltd. Immunogenic compositions for induction of anti-tumor immunity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04304897A (en) * 1991-04-01 1992-10-28 Kyowa Hakko Kogyo Co Ltd Anti-idiotype monoclonal antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025647A1 (en) * 1992-06-15 1993-12-23 The Procter & Gamble Company Liquid laundry detergent compositions with silicone antifoam agent
WO1998056416A1 (en) * 1997-06-09 1998-12-17 Yeda Research And Development Co. Ltd. Immunogenic compositions for induction of anti-tumor immunity

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BAUM R P ET AL: "ACTIVATING ANTI-IDIOTYPIC HUMAN ANTI-MOUSE ANTIBODIES FOR IMMUNOTHERAPY OF OVARIAN CARCINOMA", CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 73, no. 3, SUPPL, 1 February 1994 (1994-02-01), pages 1121 - 1125, XP008009941, ISSN: 0008-543X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, ALLEN MICHAEL H ET AL: "E-selectin binds to squamous cell carcinoma and keratinocyte cell lines.", XP002225407, Database accession no. PREV199698778164 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, STEINBACH FRANK ET AL: "The influence of cytokines on the adhesion of renal cancer cells to endothelium.", XP002225406, Database accession no. PREV199698681903 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, WALTER ULRIKE M ET AL: "The role of E- and P-selectin in neutrophil and monocyte migration in adjuvant-induced arthritis in the rat.", XP002225405, Database accession no. PREV199799611651 *
EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 27, no. 6, 1997, pages 1498 - 1505, ISSN: 0014-2980 *
JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 106, no. 4, 1996, pages 611 - 615, ISSN: 0022-202X *
JOURNAL OF UROLOGY, vol. 155, no. 2, 1996, pages 743 - 748, ISSN: 0022-5347 *
QI W ET AL: "Induction of idiotype network to anti-MUC-1 antibody in breast cancer", CHEMICAL ABSTRACTS + INDEXES, AMERICAN CHEMICAL SOCIETY. COLUMBUS, US, vol. 39, March 1998 (1998-03-01), pages 367, XP002155186, ISSN: 0009-2258 *
TRAUGOTT UTE: "L-selectin monoclonal antibody treatment of chronic experimental allergic encephalomyelitis triggers immunomodulation by the idiotypic network.", NEUROLOGY, vol. 46, no. 2 SUPPL., 1996, 48th Annual Meeting of the American Academy of Neurology;San Francisco, California, USA; March 23-30, 1996, pages A296, XP008011512, ISSN: 0028-3878 *

Also Published As

Publication number Publication date
AU782952C (en) 2006-09-07
WO2001091792A2 (en) 2001-12-06
CA2383432A1 (en) 2001-12-06
WO2001091792A9 (en) 2003-01-30
IL148351A0 (en) 2002-09-12
JP2004507459A (en) 2004-03-11
AU9016201A (en) 2001-12-11
AU782952B2 (en) 2005-09-15
EP1333859A2 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
CA2256413A1 (en) Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
BG109311A (en) PHARMACEUTICAL COMPOSITION INCLUDING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha AND THE APPLICATION THEREOF
EP2269656A3 (en) Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
IL146950A0 (en) Recombinant anti-cd40 antibody and uses thereof
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
EP0954340A4 (en) Targeted combination immunotherapy of cancer
WO2006044643A3 (en) Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2002030460A3 (en) Therapeutic antibodies
EP1383785A4 (en) Recombinant tumor specific antibody and use thereof
EE05212B1 (en) Use of a Pol Peptide for the Preparation of a Pharmaceutical Composition for the Treatment of a Tumor Cell Expressing APRIL
WO2003043583A3 (en) Treatment of immunological disorders using anti-cd30 antibodies
WO2001078779A3 (en) Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
WO2007106811A3 (en) Method and composition for treatment of renal disease with antibodies and their equivalents
WO1999063930A8 (en) Novel angiotensin receptor modulators and their uses
WO1996025947A3 (en) Induction of e-selectin for targetting therapeutic agents
WO2005102387A3 (en) Therapeutic use of anti-cs1 antibodies
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
CA2255539A1 (en) Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
Vaisitti et al. Vls-101 is a novel therapeutic antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) in Richter's syndrome (RS)
Liu et al. Recombinant single‐chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor
WO2001054706A3 (en) Method for treating kidney disorders
DK1107795T3 (en) Thiomolybdate associated with at least one carbohydrate and its use in the prevention or treatment of diseases characterized by aberrant vascularization such as cancer, wet type macular degeneration, rheumatoid arthritis
WO2001091792A3 (en) Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network
EE200000333A (en) Conjugate and Pharmaceutical Composition for the Treatment of Prostate Cancer and Methods for its Preparation
WO2004018519A3 (en) Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2383432

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 148351

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 90162/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000993870

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/30-30/30, DRAWINGS, REPLACED BY NEW PAGES 1/43-43/43; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2000993870

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 90162/01

Country of ref document: AU